PISKEL KYLE 4
4 · Adaptive Biotechnologies Corp · Filed Mar 13, 2026
Research Summary
AI-generated summary of this filing
Adaptive Biotechnologies (ADPT) CFO Kyle Piskel Sells Shares
What Happened
Kyle Piskel, CFO of Adaptive Biotechnologies (ADPT), sold 18,672 shares on 2026-03-11 at an average price of $13.17 per share, generating proceeds of $245,910. The Form 4 reports this disposition as a sale and the filing was made on 2026-03-13.
Key Details
- Transaction date and price: 2026-03-11 — 18,672 shares sold at $13.17 each (total ~$245,910).
- Transaction type: Sale (reported as open market or private sale).
- Reason/footnote: Sale was a mandated "sell to cover" to satisfy tax withholding on vested RSUs (per issuer election); not a discretionary trade by the CFO.
- Shares owned after transaction: Not disclosed on the provided summary of the filing.
- Filing timeliness: Form 4 filed 2026-03-13 — appears timely (filed within two business days of the transaction).
Context
"Sell to cover" transactions are routine tax-withholding sales tied to RSU vesting and generally do not indicate the insider's market view. This was a tax-driven disposition rather than an independent decision to liquidate holdings.
Insider Transaction Report
Form 4
PISKEL KYLE
Chief Financial Officer
Transactions
- Sale
Common Stock
[F1]2026-03-11$13.17/sh−18,672$245,910→ 259,840 total
Footnotes (1)
- [F1]This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
Signature
/s/ Kyle Piskel|2026-03-13